Alzheimer’s drug stocks to EXPLODE? 3 under-the-radar biotechs racing to beat Nautilus in Tau research.

**The landscape of Alzheimer's disease drug development is rapidly evolving, with several biotech companies making significant strides in this area.** Here are some insights into the current state and future prospects of Alzheimer's drug stocks: 1. **Eisai, Biogen, and Eli Lilly Lead the Way**: Eisai and Biogen are co-commercializing Aduhelm, the first new compound approved for Alzheimer's in a decade, with Leqembi recently joining the market. Eli Lilly has shown promise with its drug candidate donanemab, which has reported positive results and is expected to be approved by the end of the year. 2. **NewAmsterdam Pharma’s Obicetrapib Shows Promise**: Obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been shown to reduce key Alzheimer's disease biomarkers, such as p-tau217, in a cardiovascular outcomes trial. This suggests potential in targeting both cardiovascular and neurodegenerative risk. 3. **Pipeline Analysis**: The market is highly competitive, with companies like BioVie, AB Science, Cassava Sciences, and others developing novel therapies. The Alzheimer's disease market is predicted to surge, driven by the global population's aging and the rising prevalence of Alzheimer's. In conclusion, while there is no cure for Alzheimer's yet, significant progress is being made in treatment development. Companies like Eisai, Biogen, and Eli Lilly, along with NewAmsterdam Pharma, are at the forefront of this research. The market is expected to grow substantially, offering potential investment opportunities in biotech stocks focused on Alzheimer's disease treatment.